Published in Gynecol Oncol on October 01, 2004
DOXIL for Consolidation Therapy in Ovarian Cancer. | NCT00248248
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2014) 1.20
Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J (2011) 1.14
Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine (2006) 1.13
Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol (2010) 1.12
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer (2009) 1.07
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res (2011) 1.04
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release (2012) 1.04
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol (2013) 0.96
A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin Trials (2010) 0.94
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci (2016) 0.90
Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (2011) 0.87
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer (2006) 0.87
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer (2011) 0.87
Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. Cancer Biol Ther (2014) 0.86
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med (2013) 0.86
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res (2011) 0.85
Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag (2010) 0.85
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol (2011) 0.85
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Contemporary quality of life issues affecting gynecologic cancer survivors. Hematol Oncol Clin North Am (2011) 0.84
The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist (2013) 0.83
The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp Oncol (Pozn) (2013) 0.83
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J Immunol Res (2014) 0.82
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. Cancer (2014) 0.81
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer (2013) 0.80
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol (2010) 0.80
Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol (2013) 0.80
Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol (2010) 0.80
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Br J Cancer (2006) 0.79
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther (2013) 0.78
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol (2010) 0.78
Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag (2009) 0.78
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. J Cancer Res Clin Oncol (2008) 0.78
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer (2011) 0.77
Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. Angew Chem Int Ed Engl (2017) 0.77
Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics (2014) 0.77
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog (2014) 0.76
Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer. Int J Clin Oncol (2008) 0.76
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World J Clin Oncol (2012) 0.75
Adjusting for misclassification in a stratified biomarker clinical trial. Stat Med (2014) 0.75
Management of relapsed ovarian cancer: a review. Springerplus (2016) 0.75
The potential of polymeric micelles in the context of glioblastoma therapy. Front Pharmacol (2013) 0.75
Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol (2016) 0.75
Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer. BMJ Case Rep (2015) 0.75
The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer. Oncol Lett (2010) 0.75
New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res (2010) 0.75
NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY. Nano Life (2013) 0.75
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. Int J Mol Sci (2017) 0.75
Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens. Int J Clin Oncol (2011) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. Obstet Gynecol Sci (2017) 0.75
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 3.81
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 3.64
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet (2013) 1.19
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood (2002) 1.16
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood (2007) 1.13
A fluorescence detection platform using spatial electroluminescent excitation for measuring botulinum neurotoxin A activity. Biosens Bioelectron (2008) 0.99
Miniaturized 96-well ELISA chips for staphylococcal enterotoxin B detection using portable colorimetric detector. Anal Bioanal Chem (2009) 0.95
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2007) 0.95
A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs (2002) 0.92
Allometric scaling of pegylated liposomal anticancer drugs. J Pharmacokinet Pharmacodyn (2011) 0.90
An automated point-of-care system for immunodetection of staphylococcal enterotoxin B. Anal Biochem (2011) 0.89
Lab-On-a-Chip for carbon nanotubes based immunoassay detection of Staphylococcal Enterotoxin B (SEB). Lab Chip (2010) 0.84
A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist (2007) 0.83
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol (2012) 0.82
A simple 96 well microfluidic chip combined with visual and densitometry detection for resource-poor point of care testing. Sens Actuators B Chem (2011) 0.82
A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol (2010) 0.81
The use of tricorticocancellous bone graft in severely comminuted intra-articular fractures of the distal radius. J Hand Surg Am (2006) 0.80
Lab-on-a-chip for label free biological semiconductor analysis of staphylococcal enterotoxin B. Lab Chip (2010) 0.80
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol (2015) 0.79
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist (2007) 0.78
Electrical percolation-based biosensor for real-time direct detection of staphylococcal enterotoxin B (SEB). Biosens Bioelectron (2010) 0.78
Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) (2007) 0.77
Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. J Support Oncol (2005) 0.75